Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company has launched the first triple fixed-dose combination of Teneligliptin with Pioglitazone and Metformin in India.
Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name Zita®-PioMet and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation. This offers patients with Type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.
On the occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd., said, “Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38% compared to the global incidence of 15%. Being a leader in diabetes therapy in the country, we are proud to introduce Zita®-PioMet, India’s first triple fixed-dose combination for high insulin-resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve glycemic control among adult patients with high HbA1c.”